Clinical study of Angong Niuhuang Pill on acute ischemic brain injury

Not Applicable

• Conditions: Ischemic stroke

• Registration Number: ITMCTR2100005279
• Lead Sponsor: The first people's Hospital of Yuhang District, Hangzhou City, Zhejiang Province

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Over 18 years old;

(2) Acute severe ischemic stroke (NIHSS score > 15);

(3) Within 24 hours of onset;

(4) The diagnosis of cerebral infarction was in line with the standards of Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018;

(5) The patient or the patient's agent signs the informed consent form.

Exclusion Criteria

(1) Patients with acute cerebral infarction receiving thrombolysis or surgery;

(2) Patients with end-stage status at admission (GCS score < 5 or mydriasis fixed);

(3) History of intracranial hemorrhage, intracranial space occupying, brain trauma or other brain diseases;

(4) Patients with severe liver insufficiency (CTP grade B or above) and severe renal insufficiency (CCR < 30ml / min);

(5) Patients with primary diseases and malignant tumors of hematopoietic system and immune system;

(6) Patients who refused or withdrew from the study due to various reasons.

Study & Design

• Study Type: Treatment study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28 day mortality;

Secondary Outcome Measures

Name	Time	Method
Blood arsenic concentration;Urinary mercury concentration;Urinary arsenic concentration;Blood mercury concentration;Improvement rate of early consciousness;